|1.||Kohno, Kimitoshi: 11 articles (12/2015 - 04/2002)|
|2.||Izumi, Hiroto: 7 articles (12/2015 - 04/2002)|
|3.||Kohno, K: 5 articles (07/2013 - 09/2002)|
|4.||Clausen, Henrik: 5 articles (06/2012 - 07/2006)|
|5.||Osinaga, Eduardo: 5 articles (03/2008 - 01/2003)|
|6.||Izumi, H: 4 articles (07/2013 - 09/2002)|
|7.||Mandel, Ulla: 4 articles (06/2012 - 07/2006)|
|8.||Wu, Shiliang: 3 articles (12/2012 - 11/2011)|
|9.||Xu, Lan: 3 articles (12/2012 - 11/2011)|
|10.||Bennett, Eric P: 3 articles (06/2012 - 01/2007)|
03/15/2004 - "In this study, immunohistochemistry was performed to determine the expression level of GalNAc-T3 in 34 cases of pT(2) gallbladder carcinoma to determine the correlation of the GalNAc-T3 expression level with mode of recurrence and postsurgical survival. "
01/01/2003 - "In the present study, we investigated the relationship between immunohistochemical GalNAc-T3 expression and various clinicopathologic factors, including prognosis, in 117 gastric carcinoma patients. "
04/01/1995 - "Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase from milk or mammary carcinoma cells."
12/01/2013 - "GalNAc-T3 was expressed in 40% and 20% of well and poorly differentiated components of follicular carcinomas, respectively. "
01/01/2012 - "To investigate the effect of glycopeptide-preferring polypeptide GalNAc transferase 1 (ppGalNAc T1) targeted RNA interference (RNAi) on the growth and migration of human bladder carcinoma EJ cells in vitro and in vivo. "
01/30/2014 - "Previously, we have identified the polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3) gene as notably hypomethylated in low-malignant potential (LMP) and high-grade (HG) serous epithelial ovarian tumors, compared to normal ovarian tissues. "
02/01/2007 - "There were no significant correlations between the GalNAc-T3 expression patterns and other clinicopathological factors, including tumor differentiation, depth of invasion or overall survival. "
04/01/2004 - "Although the expression of GalNAc-T3 has been examined in various cancers, the expression has not been characterized in early stages of cancer. "
01/01/2004 - "A close association was observed between GalNAc-T3 staining intensity and histologic differentiation and the stage of the tumors. "
01/01/2004 - "Thirty-five tumors showed high- intensity GalNAc-T3 staining, whereas 24 showed low-intensity staining. "
01/01/2004 - "In the present study, the association of GalNAc-T3 expression with clinicopathologic features of pancreatic adenocarcinoma and patients' survival was examined. "
01/01/2015 - "The low expression of the GalNAc-T3 usually in adenocarcinoma cell lines was compared with normal bronchial epithelium cell line. "
01/01/2004 - "These findings indicate that the expression of GalNAc-T3 is associated with the differentiation and aggressiveness of ductal adenocarcinoma of the pancreas."
11/01/1997 - "Well-differentiated adenocarcinoma cell lines expressed high levels and moderately differentiated cell lines expressed lower levels of GalNAc-T3. "
11/01/1997 - "We propose that glycosylation in tumor cell lines may be regulated in part by differential expression of GalNAc-transferases, and we suggest that GalNAc-T3 gene expression may be a molecular indicator of differentiated adenocarcinoma."
|4.||Lung Neoplasms (Lung Cancer)
09/23/2002 - "In the present study, we used immunohistochemistry to examine GalNAc-T3 expression in 215 surgically resected non-small cell lung cancers. "
09/23/2002 - "These results suggest that GalNAc-T3 is a new marker of non-small cell lung cancers with specificity for histology and prognosis."
09/23/2002 - "Low GalNAc-T3 expression was an unfavourable prognostic factor in pStage I non-small cell lung cancers (hazards ratio, 2.04; P=0.03), and in pStage I nonsquamous cell carcinomas (hazards ratio, 2.70; P=0.03). "
09/23/2002 - "Patients with low GalNAc-T3 expression survived a significantly shorter time than patients with high GalNAc-T3 expression in 103 pStage I non-small cell lung cancers (5-year survival rates, 58% and 78%, respectively; P=0.02 by log-rank test) as well as in 61 pStage I nonsquamous cell carcinomas (5-year survival rates, 63% and 85%, respectively; P=0.03). "
01/01/2015 - "Expression of GalNAc-T3 was examined using immunohistochemistry staining on primary tumor specimens, and the tumors were reclassified in light of the IASLC/ATS/ERS (International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society) adenocarcinoma classifications followed by grading and scoring. "
|5.||Stomach Neoplasms (Stomach Cancer)
04/15/2014 - "Our studies were designed to investigate the expression and prognostic values of GalNAc-T5 and improve the risk stratification in patients with gastric cancer. "
04/15/2014 - "Detection of GalNAc-T5 expression in gastric cancer tissues might add some prognostic information for patients with this disease and lead to a more accurate classification under the TNM stage system."
04/15/2014 - "Intratumoral GalNAc-T5 expression was recognised as an independent prognostic marker for the overall survival of gastric cancer patients. "
04/15/2014 - "Applying the prognostic value of intratumoral GalNAc-T5 density to the conventional clinicopathologic TNM stage system showed a better prognostic value in patients with gastric cancer. "
04/15/2014 - "Low intratumoral GalNAc-T5 density, which was associated with tumour cell differentiation, T classification, N classification, and TNM stage in the two independent sets, was an independent prognosticator for poor prognosis of gastric cancer patients. "
|5.||Uridine Diphosphate (UDP)
|1.||Lymph Node Excision (Lymph Node Dissection)